The capitalisation trajectory of OpenEvidence represents one of the most compressed liquidity ascents in the enterprise healthcare technology sector. Within four years of its initial backing, the company evolved from an early-stage clinical retrieval experiment into a decacorn entity valued among the largest private software companies in the world. Between early 2025 and late 2026, OpenEvidence executed a series of high-velocity funding rounds that drove an aggregate fifteenf